- PCI Biotech Holding ASA - Annual Report 2023
- PCI Biotech second half 2023 interim results
- PCI Biotech: Invitation to second half interim 2023 results presentation
- PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
- PCI Biotech: European patent for mRNA delivery with fimaNAc
- PCI Biotech: Employee share option scheme
- PCI Biotech: Write-down of share capital registered
- PCI Biotech first half 2023 interim results
- PCI Biotech: Invitation to first half interim 2023 results presentation
- Minutes from Annual General Meeting 2023
More ▼
Key statistics
On Friday, PCI Biotech Holding ASA (PCIB:OSL) closed at 1.62, 34.83% above the 52 week low of 1.20 set on Oct 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.57 |
---|---|
High | 1.62 |
Low | 1.54 |
Bid | 1.54 |
Offer | 1.60 |
Previous close | 1.62 |
Average volume | 41.75k |
---|---|
Shares outstanding | 37.33m |
Free float | 28.39m |
P/E (TTM) | -- |
Market cap | 60.47m NOK |
EPS (TTM) | -0.5443 NOK |
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼